NCT06623344Completed
Brain Volume and Cardiac Function in Heart Failure
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
Patients with heart failure (HF) exhibit greater structural brain alterations and higher dementia risks than the general population. Neural atrophy in nearly every region of medical limbic circuit has been observed in HF patients. Reduction of cerebral blood flow has been suggested as the pathophysiological pathway linking HF and structural brain changes. Indeed, lower cardiac index levels were related to lower cerebral blood flow in older adults without stroke, dementia, or heart failure. A few prior studies have examined the subcortical structural differences in patients with HF compared to controls. Brain volume loss (including putamen and hippocampal volumes) have been reported in patients with low ejection fraction. Significant gray matter loss was found in specific brain regions of HF patients and included structures that serve demonstrated roles in cognitive functions. In the investigator's previous study (Comprehensive Imaging Exam of Convalesced COVID-19 Patients - COVID-19 RELATED SUBMISSION-IRB00252436), involving 100 participants (volunteers with normal heart function (ejection fraction; 50%)), the investigators observed significant correlations between thalamic volumes and ventricular stroke volumes in volunteers. Building on these findings, the investigators intend to expand the research to include individuals with heart failure (HF), employing the same MRI protocol. The study will involve obtaining a set of T1-weighted brain images to measure the volumes of seven subcortical structures. The investigators goal is to explore the relationship between subcortical volumes and cardiac parameters. Additionally, the investigators will examine whether patients with HF experience a more rapid reduction in subcortical volumes compared to those with normal cardiac function (EF;50%).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 30 Sept 2024
- Start date
- 10 Nov 2024
- Primary completion date
- 6 Jul 2026
- Lead sponsor
- Johns Hopkins University
- Diseases
- Heart failure
- NCT number
- NCT06623344
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 10 Nov 2024 to the primary completion date, 6 Jul 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Internal electrical devices, such as cochlear implant, spinal cord stimulator, pacemaker, or defibrillator
Other illness
- Known allergy to gadolinium contrast agents
- Presence of any other history or condition that the investigator feels would be problematic
Lab values
- Glomerular filtration rate (GFR) 45 mL/min (using the Cockcroft-Gault formula)
Other
- Metal fragments in eyes, brain, or spinal cord
- Pregnancy
- Severe claustrophobia
- Weight exceeding 300 lbs. (MRI table weight restrictions)
Who the study is looking for
- Individuals with an ejection fraction (EF) below 50% who are willing to
- provide informed consent.
- Not claustrophobia.
- Age: 21 years and above.
- Ambulatory patients are eligible.
Age in the registry: 21 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Johns Hopkins Center for Advanced Imaging and Research Science, Johns Hopkins Science + Technology Park at 1812 Ashland Avenue, Baltimore, MD Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.